Pavmed INC 8-K filings

PAVmed reported its Q2 2024 financial results, highlighting record test volumes for Lucid's EsoGuard test and progress in financing for its subsidiaries.

PAVmed Inc. successfully held its annual meeting on June 20, 2024, re-electing two Class B directors and ratifying its independent auditor.

PAVmed reported its Q1 2024 financial results, highlighted by a 124% year-over-year increase in EsoGuard revenue and a strengthened balance sheet for its subsidiary Lucid Diagnostics.

Lucid Diagnostics, a majority-owned subsidiary of PAVmed, secured approximately $11.6 million through the sale of Series B-1 Convertible Preferred Stock to accredited investors.

Veris Health, a subsidiary of PAVmed, has signed a memorandum of understanding with The Ohio State University Comprehensive Cancer Center to implement a pilot program for its Veris Cancer Care Platform.

PAVmed Inc. has extended the deadline for a $2 million fee payment related to its senior secured convertible notes from April 25, 2024, to June 15, 2024.

Lucid Diagnostics, a majority-owned subsidiary of PAVmed, finalized a Series B preferred stock offering and exchange, raising $12.5 million and restructuring existing preferred shares.

PAVmed Inc. has amended its agreements with noteholders, extending the maturity dates of its senior secured convertible notes and securing a waiver on a key financial covenant.

PAVmed Inc. received a notice from Nasdaq stating that its market value of listed securities fell below the required $35 million, potentially leading to delisting if compliance is not regained within 180 days.

PAVmed Inc. distributed shares of its subsidiary, Lucid Diagnostics, to its shareholders as a special dividend and adjusted the exercise price of its Series Z Warrants.

PAVmed Inc. is distributing approximately 3,331,771 shares of Lucid Diagnostics Inc. common stock to its shareholders through a special pro rata dividend.

PAVmed Inc. has elected to receive $4.7 million in fees and reimbursements from its subsidiary, Lucid Diagnostics, through the issuance of 3.3 million shares of Lucid Diagnostics common stock.